PriceTargets.com logo

Plus Therapeutics - PSTV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.50
  • Forecasted Upside: 1,138.53%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.09 As of 12/20/2024 06:16 PM ET
▲ +0.1 (10.10%)

This chart shows the closing price for PSTV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Plus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSTV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTV

Analyst Price Target is $13.50
▲ +1,138.53% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Plus Therapeutics in the last 3 months. The average price target is $13.50, with a high forecast of $19.00 and a low forecast of $8.00. The average price target represents a 1,138.53% upside from the last price of $1.09.

This chart shows the closing price for PSTV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Plus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/9/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$20.00 ➝ $19.00
11/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
9/3/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$21.00 ➝ $20.00
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
6/30/2023HC WainwrightBoost TargetBuy$8.00
5/3/2023Maxim GroupLower Target$30.00 ➝ $12.00
4/21/2023HC WainwrightReiterated RatingBuy$52.50
10/6/2022JonestradingInitiated CoverageBuy$75.00
8/15/2022Ascendiant Capital MarketsLower Target$75.00
8/9/2022Ascendiant Capital MarketsLower Target$75.00
7/22/2022HC WainwrightLower TargetBuy$105.00 ➝ $52.50
5/26/2022Maxim GroupLower Target$30.00
4/22/2022HC WainwrightReiterated RatingBuy$105.00
2/25/2022HC WainwrightReiterated RatingBuy
7/23/2021Maxim GroupInitiated CoverageBuy$90.00
7/23/2021HC WainwrightReiterated RatingBuy$105.00
4/23/2021HC WainwrightReiterated RatingBuy$105.00
2/11/2021HC WainwrightInitiated CoverageBuy$105.00
1/25/2021LADENBURG THALM/SH SHInitiated CoverageBuy$120.00
11/20/2020Maxim GroupReiterated RatingBuy$90.00
10/23/2020Maxim GroupReiterated RatingBuy$90.00
10/16/2020Maxim GroupInitiated CoverageBuy$90.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Plus Therapeutics logo
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.09
Low: $0.97
High: $1.11

50 Day Range

MA: $1.29
Low: $0.99
High: $1.45

52 Week Range

Now: $1.09
Low: $0.93
High: $2.67

Volume

48,987 shs

Average Volume

64,415 shs

Market Capitalization

$6.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Plus Therapeutics?

The following Wall Street sell-side analysts have issued reports on Plus Therapeutics in the last year: Ascendiant Capital Markets, and HC Wainwright.
View the latest analyst ratings for PSTV.

What is the current price target for Plus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Plus Therapeutics in the last year. Their average twelve-month price target is $13.50, suggesting a possible upside of 1,138.5%. Ascendiant Capital Markets has the highest price target set, predicting PSTV will reach $19.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Plus Therapeutics in the next year.
View the latest price targets for PSTV.

What is the current consensus analyst rating for Plus Therapeutics?

Plus Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSTV will outperform the market and that investors should add to their positions of Plus Therapeutics.
View the latest ratings for PSTV.

What other companies compete with Plus Therapeutics?

Other companies that are similar to Plus Therapeutics include Femasys, Co-Diagnostics, DarioHealth, Vivos Therapeutics and Allurion Technologies. Learn More about companies similar to Plus Therapeutics.

How do I contact Plus Therapeutics' investor relations team?

Plus Therapeutics' physical mailing address is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. The company's listed phone number is 737-255-7194 and its investor relations email address is [email protected]. The official website for Plus Therapeutics is www.plustherapeutics.com. Learn More about contacing Plus Therapeutics investor relations.